Integer Holdings Corporation (NYSE: ITGR) – Investigated by Federman & Sherwood
January 15, 2026– The law firm of Federman & Sherwood, a nationally recognized plaintiffs’ litigation firm representing shareholders and investors in complex securities matters, today announced that it has initiated an independent investigation into potential securities law violations by Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR) on behalf of purchasers of the Company’s common stock during the period from July 25, 2024 through October 22, 2025 (the “Class Period”).
Details of the Investigation:
Federman & Sherwood’s investigation focuses on whether Integer and certain of its officers and directors made materially false or misleading statements, and/or failed to disclose material information to investors regarding the Company’s business, operations, and prospects. According to allegations raised in a recently filed securities action, Integer may have:
- Overstated its competitive position within the growing electrophysiology (“EP”) device manufacturing market.
- Claimed strong visibility into customer demand despite experiencing a sustained decline in sales of key EP products.
- Mischaracterized EP devices as a long-term growth driver for its Cardio & Vascular segment, contrary to internal performance realities.
- Made positive public statements about its business and prospects that were materially false, misleading, or lacked a reasonable basis at the time they were made.
The investigation also is examining whether the Company’s corrective disclosures — including an announcement lowering full-year sales guidance and projecting net sales growth materially below prior expectations — were preceded by undisclosed adverse information that impacted the trading price of Integer common stock and caused significant investor losses.
Background:
Integer Holdings Corporation is a global medical device design, development, and manufacturing company whose products include cardiac rhythm management and cardiovascular devices. During the Class Period, Integer publicly promoted its performance and growth prospects in the electrophysiology market while internal demand for certain products was allegedly weakening. Following revised guidance, the Company’s stock price declined significantly, harming investors who relied on prior public statements.
What This Means for Investors:
Investors who purchased Integer Holdings Corporation common stock during the Class Period and suffered financial losses may contact Federman & Sherwood for a free and confidential consultation. The firm is evaluating potential legal claims and all available remedies on behalf of affected shareholders.
CONTACT FEDERMAN & SHERWOOD
Attorney Sara Collier is widely regarded as a leading attorney in the field of derivative shareholder litigation. She is driven by a deep commitment to ensuring that boards of directors and corporate executives of publicly traded companies answer to the shareholders they serve.
With over ten years of experience pursuing derivative cases nationwide—particularly in Delaware, the home jurisdiction for many major corporations—Ms. Collier has developed a reputation for skillfully pushing even the largest companies toward stronger transparency and accountability in their corporate governance.
Phone: (405) 235-1560
Contact Form
Email : sec@federmanlaw.com